Transcode Therapeutics (RNAZ) Interest & Investment Income (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Interest & Investment Income came in at $91888.0 in Q1 2026, up 62836.99% YoY from N/an in Q1 2025, and up 16.67% on a QoQ basis from $78757.0 in Q4 2025.
Transcode Therapeutics (RNAZ) Interest & Investment Income (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Interest & Investment Income data on file, last reported at $91888.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 62836.99% year-over-year to $91888.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $170940.0 (up 25721.75% YoY) and the FY2025 annual result came in at $79198.0, up 11478.65% from the prior year.
- Interest & Investment Income climbed to $91888.0 in Q1 2026, from $78757.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $91888.0 in Q1 2026 to a low of $131.0 in Q3 2023.
- A 5-year average of $11615.5 and a median of $179.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 133000.0% — and 2023, when it sank 98.58%.
- Tracing RNAZ's Interest & Investment Income over 5 years: stood at $9636.0 in 2022, then slumped by 98.58% to $137.0 in 2023, then increased by 16.06% to $159.0 in 2024, then jumped by 49432.7% to $78757.0 in 2025, then rose by 16.67% to $91888.0 in 2026.
- The last three Interest & Investment Income figures came in at $91888.0 (Q1 2026), $78757.0 (Q4 2025), and $147.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 52,168.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91,888.00 |
| Dec 31, 2025 | 78,757.00 |
| Sep 30, 2025 | 147.00 |
| Jun 30, 2025 | 148.00 |
| Mar 31, 2025 | 146.00 |
| Dec 31, 2024 | 159.00 |
| Sep 30, 2024 | 179.00 |
| Jun 30, 2024 | 178.00 |
| Mar 31, 2024 | 168.00 |
| Dec 31, 2023 | 137.00 |
| Sep 30, 2023 | 131.00 |
| Jun 30, 2023 | 246.00 |
| Mar 31, 2023 | 4,770.00 |
| Dec 31, 2022 | 9,636.00 |
| Sep 30, 2022 | 9,001.00 |
| Jun 30, 2022 | 1,331.00 |
| Mar 31, 2022 | 442.00 |
| Dec 31, 2021 | 510.00 |
| Sep 30, 2021 | 141.00 |
| Jun 30, 2021 | 1.00 |